



Current Agreements

Dealdoc

Joint venture and licensing agreement for new company and products

Takeda Pharmaceutical
Medipal Holdings
Innovation Network Corporation
Scohia Pharma

Mar 14 2017

Joint venture and licensing agreement for new company and products

Companies:

[Takeda Pharmaceutical](#)
[Medipal Holdings](#)
[Innovation Network Corporation](#)
[Scohia Pharma](#)

Announcement date:

Mar 14 2017

Deal value, US\$m:

90.13 : sum of investment

- [Details](#)
- [Financials](#)
- [Termsheet](#)
- [Press Release](#)
- [Filing Data](#)
- [Contract](#)

Details

Announcement date:

Mar 14 2017

Industry sectors:

Bigpharma
Financial
Pharmaceutical
Services

Asset type:

Business
Cardiovascular

Therapy areas:

Genitourinary
Metabolic

Deal components:

Joint venture
Licensing

Financials

Deal value, US\$m:

90.13 : sum of investment

Termsheet

Innovation Network Corporation of Japan , Takeda Pharmaceutical Company Limited), and MEDIPAL HOLDINGS CORPORATION have agreed to jointly invest a total of 10 billion yen to establish a new company, which will be named SCOHIA PHARMA, Inc.

Following its launch within Takeda's Shonan Research Center, SCOHIA PHARMA will sign a license agreement with Takeda for eight of Takeda's renal, metabolic and cardiovascular research and development projects,* with the goal of initiating operations on April 1, 2017.

Takeda researchers with a high level of expertise in and knowledge of these therapeutic areas will be involved in SCOHIA PHARMA's activities.

SCOHIA PHARMA, as a biotech venture that will have both substantial research and development resources and be nimble enough to make decisions quickly, will strive to improve patient quality of life by providing patients and healthcare professionals with new therapeutic medications for renal, metabolic, and cardiovascular diseases.

Press Release

Enhancing the international competitiveness of the Japanese pharmaceutical companies by offering spin-off model Takeda will contribute the research and development portfolio and personnel in the renal, metabolic, and cardiovascular therapeutic areas to support the launch of the new company This venture, a large-scale public-private project incorporating a pharmaceutical company and a major distributor, represents an entirely new drug discovery and open innovation ecosystem Tokyo and Osaka, Japan, March 14, 2017 - Innovation Network Corporation of

Japan (headquarters: Chiyoda-ku, Tokyo; President and COO: Mikihide Katsumata; "INCJ"), Takeda Pharmaceutical Company Limited (headquarters: Chuo-ku, Osaka; President and CEO: Christophe Weber; "Takeda"), and MEDIPAL HOLDINGS CORPORATION (headquarters: Chuo-ku, Tokyo; President and CEO: Shuichi Watanabe; "MEDIPAL HD") have agreed to jointly invest a total of 10 billion yen to establish a new company, which will be named SCOHIA PHARMA, Inc. ("SCOHIA PHARMA") Following its launch within Takeda's Shonan Research Center, SCOHIA PHARMA will sign a license agreement with Takeda for eight of Takeda's renal, metabolic and cardiovascular research and development projects, *with the goal of initiating operations on April 1, 2017. Takeda researchers with a high level of expertise in and knowledge of these therapeutic areas will be involved in SCOHIA PHARMA's activities. SCOHIA PHARMA, as a biotech venture that will have both substantial research and development resources and be nimble enough to make decisions quickly, will strive to improve patient quality of life by providing patients and healthcare professionals with new therapeutic medications for renal, metabolic, and cardiovascular diseases. Mikihide Katsumata, President and COO at INCJ, said "When US and European pharmaceutical companies execute an essential strategic shift, spin-off biotech ventures are formed on a constant basis, which consequently provides greater flexibility in corporate resources including product development, drug discovery and human resources. SCOHIA PHARMA will be born as a remarkably large-scale biotech venture with proven development pipelines, and I anticipate that its success will contribute not only to the delivery of new therapeutic medications but also to the establishment of an entire new ecosystem in the Japanese pharmaceutical industry and biotech field."* Andy Plump, M.D., Ph.D., Director, Chief Medical and Scientific Officer at Takeda, said "Takeda has been transforming its research and development organization in order to deliver innovative new medicines for patients. The establishment of SCOHIA PHARMA represents not only a business model that will allow a high level of expertise to be brought to bear over an extended period of time in the renal, metabolic, and cardiovascular therapeutic areas, but is also an early step in the creation of a research park that will allow Takeda's Shonan Research Center to gather a wide variety of healthcare knowledge in one location. I believe that as a drug discovery venture company with its origin in Japan, SCOHIA PHARMA will be able to deliver new value to patients." MEDIPAL HD Managing Director Toshihide Yoda said that "MEDIPAL, which plays a core role in the domestic distribution activities of Takeda, will through its investment in SCOHIA PHARMA contribute to society by providing added value to the supply chain from the drug discovery stage through the distribution stage, thereby guaranteeing 'the stable supply of pharmaceuticals.'" Yoichi Okumura, who has been appointed as the CEO of SCOHIA PHARMA, said that "SCOHIA PHARMA will allow world-class scientists to realize their full potential, and the creative forces that will be generated as a result will ensure that suffering patients will have access to new treatment options. SCOHIA PHARMA will show a new business model to the Japanese business industry how large domestic pharmaceutical companies successfully spin off a venture company."

Eight research and development projects

Code	Expected Indication(s)	Stage of Development
TAK-272	Early stage diabetic nephropathy/hypertension	Phase 2
TAK-792	Obesity	Phase 1
TAK-094	Diabetes	Preclinical
And 5 other products		that are in the preclinical or drug discovery stage

Overview of SCOHIA PHARMA

1. Name SCOHIA PHARMA, Inc.
2. Address 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa (Within Takeda's Shonan Research Center)
3. Representative director CEO: Yoichi Okumura
4. Business Drug product research, development, manufacturing, and marketing
5. Capitalization 5 billion yen
6. Major shareholders and ownership stakes INCJ 70.5% Takeda 19.5% MEDIPAL HD 10.0%

About Innovation Network Corporation of Japan (INCJ) INCJ was established in July 2009 as a public-private investment company that provides financial, technological and management support for next-generation businesses. INCJ specifically supports those projects that combine technologies and varied expertise across industries and materialize open innovation. INCJ has the capacity to invest up to JPY2 trillion (approx. US\$20 billion). INCJ's management team is drawn from the private sector with diverse experience in investment, technologies and management. Through its Innovation Network Committee, INCJ assesses investment opportunities that contribute to industrial innovation in Japan in line with criteria set by the government. <http://www.incj.co.jp/english/> About Takeda Pharmaceutical Company Takeda Pharmaceutical Company Limited is a global, research and development-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines. Takeda focuses its R&D efforts on oncology, gastroenterology and central nervous system therapeutic areas plus vaccines. Takeda conducts R&D both internally and with partners to stay at the leading edge of innovation. New innovative products, especially in oncology and gastroenterology, as well as our presence in Emerging Markets, fuel the growth of Takeda. More than 30,000 Takeda employees are committed to improving quality of life for patients, working with our partners in health care in more than 70 countries. For more information, visit <http://takeda.com/>

Filing Data

Not available.

Contract

Not available.